Retraction
The authors wish to retract this article at the request of the Scottish Haemophilus Legionella Meningococcus Pneumococcus Reference Laboratory (SHLMPRL). Although the work was part of an independently-funded research grant awarded to Stuart Clarke, Matthew Diggle and Robert Davies by the Scottish Executive, they did not have permission from the current SHLMPRL management to publish the data in their current form. The anonymised data in the MLST database will remain available. The authors apologise to the readers.
16 Oct 2015: Sullivan CB, Diggle MA, Davies RL, Clarke SC (2015) Retraction: Clonal Analysis of Meningococci during a 26 Year Period Prior to the Introduction of Meningococcal Serogroup C Vaccines. PLOS ONE 10(10): e0141008. https://doi.org/10.1371/journal.pone.0141008 View retraction
Figures
Abstract
Meningococcal disease remains a public health burden in the UK and elsewhere. Invasive Neisseria meningitidis, isolated in Scotland between 1972 and 1998, were characterised retrospectively to examine the serogroup and clonal structure of the circulating population. 2607 isolates causing invasive disease were available for serogroup and MLST analysis whilst 2517 were available for multilocus sequence typing (MLST) analysis only. Serogroup distribution changed from year to year but serogroups B and C were dominant throughout. Serogroup B was dominant throughout the 1970s and early 1980s until serogroup C became dominant during the mid-1980s. The increase in serogroup C was not associated with one particular sequence type (ST) but was associated with a number of STs, including ST-8, ST-11, ST-206 and ST-334. This is in contrast to the increase in serogroup C disease seen in the 1990s that was due to expansion of the ST-11 clonal complex. While there was considerable diversity among the isolates (309 different STs among the 2607 isolates), a large proportion of isolates (59.9%) were associated with only 10 STs. These data highlight meningococcal diversity over time and the need for ongoing surveillance during the introduction of new meningococcal vaccines.
Citation: Sullivan CB, Diggle MA, Davies RL, Clarke SC (2015) Clonal Analysis of Meningococci during a 26 Year Period Prior to the Introduction of Meningococcal Serogroup C Vaccines. PLoS ONE 10(1): e115741. https://doi.org/10.1371/journal.pone.0115741
Editor: Caroline L. Trotter, University of Cambridge, United Kingdom
Received: July 7, 2014; Accepted: November 20, 2014; Published: January 23, 2015
Copyright: © 2015 Sullivan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. Relevant data are available at: http://pubmlst.org/neisseria/.
Funding: This work was funded by the Chief Scientist's Office of the Scottish Executive (grant number CZB/4/28) awarded to SCC, MAD and RLD. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have read the journal's policy and have the following competing interests: SCC currently receives unrestricted research funding from Pfizer Vaccines (previously Wyeth Vaccines) and research funding from GSK. SCC has received financial assistance from vaccine manufacturers to attend conferences. All grants and honoraria are paid into accounts within the respective NHS Trusts or Universities, or to independent charities. CBS, MAD and RLD have declared that no competing interests exist. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Introduction
Neisseria meningitidis is an important cause of meningitis and bacteraemia worldwide. The UK has experienced a changing meningococcal epidemiology in recent decades, which may be due to the cyclical pattern seen in meningococcal serogroups as well as the implementation of meningococcal serogroup C (MenC) vaccines [1], [2]. A MenC immunisation programme was implemented in the UK in 1999. The vaccine was highly effective in reducing the incidence of serogroup C meningococcal disease and associated mortality, with no immediate adverse effects on other serogroups [3]–[5]. However, the natural history of meningococcal epidemiology is not well understood, particularly in relation to the long-term effect of MenC immunisation on the meningococcal population. It is therefore vital that the surveillance of meningococcal disease is continued. Long-term retrospective data is required as most contemporary information relates to immediately prior to or after the implementation of MenC vaccines. Although data is available on meningococcal serogroups dating back to the 1970s, and serogroup and serotype data is available from the 1990s, there is little molecular data available from the 1970s onwards. Using the collection held at the Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory (SHLMPRL) from 1972 onwards, we describe the serogroup and clonal diversity of N. meningitidis in Scotland over several decades prior to the introduction of MenC vaccines.
Materials and Methods
Ethical approval
This work was carried out as part of routine public health investigations by the Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory. The SHLMPRL is the national reference service for the detection and characterization of human Haemophilus, Legionella, Meningococcus and Pneumococcus infections and the identification and typing of associated environmental isolates. Patient consent was not required for this work. All data was anonymised and only bacterial isolates were used; no human tissue or clinical samples were used.
Bacterial isolates
All isolates of N. meningitidis from blood, cerebrospinal fluid (CSF) and other normally sterile sites received by the SHLMPRL between 1972 and 1998 were included in the study. Isolates originated from patients with reported invasive meningococcal disease and were isolated at local diagnostic microbiology laboratories in all NHS regions across Scotland. Only one isolate was used per patient. Isolates were resuscitated from freeze-dried ampules in archive storage at the SHLMPRL by culturing on Columbia horse blood agar (Oxoid, Basingstoke, UK) and incubated overnight at 37°C in 5% CO2.
DNA extraction
DNA was isolated as previously described [6] and used directly for PCR. For those freeze-dried meningococci that were not recoverable by culture, DNA was amplified directly from the freeze-dried vial.
Isolate characterisation
Serogrouping was performed by latex agglutination when the meningococcal isolates were first submitted to the reference laboratory [7]. Those found to be non-groupable were characterised using siaD and mynA PCR as previously described [8]–[10]. Molecular characterisation was performed by multilocus sequence typing (MLST) based upon a semi-automated procedure [11]. The analysis of nucleotide sequence data and assignment of alleles and assignment of the allelic profile (otherwise known as the sequence type, ST) were performed as previously described [4], [12]. Clonal comparisons were made using eBURST2 [13].
Results
Serogroup characterisation
2607 isolates of N. meningitidis were available for analysis. 1434 were from CSF, 913 from blood and 260 from other sites (including skin scraping, joint aspirate, brain tissue, eye swab and rash fluid). There were 147 serogroup A isolates (5.6%), 1446 serogroup B isolates (55.5%), 812 serogroup C isolates (31.1%), 37 serogroup Y isolates (1.4%), 67 serogroup W isolates (2.6%), 10 serogroup X isolates (0.4%), five serogroup Z isolates (0.2%) and six serogroup E isolates (0.2%). Eighty-two isolates were initially non-groupable using latex agglutination but PCR reduced that number to 19 (0.7%). A further 58 isolates (2.2%) could not be characterised using either serogrouping or MLST by phenotypic or molecular methods. Serogroup distribution changed from year to year. Serogroup A meningococci were associated with 143 cases of invasive disease. The incidence of serogroup A was higher during the 1970s before declining substantially. 134 isolates (94%) occurred between 1973 and 1982, followed by three cases in 1986, two cases in 1987, one in 1989, one in 1992 and two in 1995. Serogroups B and C were the dominant serogroups during the 1980s and 1990s (Fig. 1). Serogroups Y, WI35, X, Z and E were also present in Scotland over this time period, representing only 4.8% of the total.
Clonal analysis by MLST
There were 309 different STs with ten accounting for 1562 isolates (59.9%). These were ST-11 (14.3%), ST-8 (14.2%), ST-41 (8.1%), ST-153 (5.4%), ST-1 (4.9%), ST-32 (3.9%), ST-33 (2.9%), ST-269 (2.5%), ST-334 (1.9%) and ST-60 (1.9%). The STs grouped into 31 distinct lineages, with 67 singleton types. There were 177 new STs which accounted for 253 (9.7%) isolates. The ST-8 complex was predominant, accounting for 567 isolates (21.7%) (Table 1). This was represented by 21 different STs, the predominant being ST-8 (369, 65.1%), ST-153 (a gdh locus variant of ST-8) (141, 24.9%), and ST-66 (a fumC locus variant of ST-8) (18, 3.2%).
MLST analysis by decade and serogroup
To determine the changes that might have occurred within the meningococcal population during the study period, analysis was performed by splitting the data into the time periods 1972–1979, 1980–1989 and 1990–1998, to fit with the suspected timing of the clonal expansion of MenC during the 1990s. Between 1972 and 1979 there were 616 isolates and these comprised 54 STs. There were 20 different clonal complexes and five singletons. Between 1980 and 1989 there were 845 isolates and these comprised 182 STs. There were 25 different clonal complexes and 39 singletons. Between 1990 and 1998 there were 1146 isolates comprising 160 STs. There were 27 different clonal complexes and 31 singletons.
The ST-8 complex was predominant during the 1980s and 1990s but declined from 1993 in line with an increase in ST11. The ST41/44 complex was the next most common during the 1980s and 1990s, two-thirds of which were serogroup B. he ST-11 complex became dominant during the 1990s which was associated with the specific emergence of serogroup C ST-11 meningococci and which coincided with a reduction in the ST-8 strains which had been predominant during the 1980s and early parts of the 1990s.
Serogroup B isolates could be differentiated into 218 different STs, comprising 20 distinct lineages with 54 singleton types. Three lineages accounted for 888 isolates. The ST-41/44 complex was predominant with 333 isolates (23.0%) and these were divided into 42 different STs.
Serogroup C isolates could be differentiated into 84 different STs, comprising 13 thirteen distinct lineages with 11 singleton types. Three lineages accounted for 664 isolates which represented 81.7% of all serogroup C isolates. The ST-11 complex accounted for the majority of isolates (328, 40.4%), these were divided into eight STs, 314 were ST-11 (95.7%), three were ST-2510, three were ST-4644, two were ST-3298 and ST-67, ST-2942, ST-3455 and ST-4677 were represented by a single isolate. The ST-8 complex accounted for 243 isolates (29.9%) and they were divided into nine different STs, 208 were ST-8 (85.6%), 15 were ST-66 (6.2%), and 13 were ST-153 (5.3%). Serogroup C was initially not associated with a particular clone but the major STs included ST-8, ST-11, ST-206 and ST-334.
Nine STs were associated with serogroup A meningococci (ST-1, ST-5, ST-60, ST-2002, ST-2174, ST-2152, ST-2517, ST-4570 and ST-4571). However, 88.7% of isolates were ST-1. Serogroup Y isolates could be differentiated into 10 different STs within three distinct lineages, with four singleton types. The ST-23 complex was predominant accounting for 19 (51.4%) isolates of which six were isolated in the 1970s, five in the 1980s and eight in the 1990s. Serogroup W isolates could be differentiated into 11 different STs within four distinct lineages, with two singleton types. The ST-11 complex was predominant with 42 isolates.
Discussion
Our long-term, nationwide study has provided a unique insight into the molecular epidemiology of meningococci causing invasive disease within Scotland in the period 1972–1998. Using serogroup and MLST data we have described the clonal distribution of invasive meningococci prior to and during the emergence of MenC disease in the UK. Our data complements that described in other studies performed during the implementation of MenC vaccines [2], [4], [14], [15].
Serogroup distribution changed from year to year in Scotland during the time period 1972–1998, but serogroups B and C were dominant. Serogroup A was present within the 1970s and early 1980s but has not re-established itself as a major cause of meningococcal disease in the UK or elsewhere in Europe [16]. Serogroup B was the predominant serogroup throughout the 1970s and early 1980s until serogroup C became predominant during the mid-1980s. Although serogroup Y meningococcal disease was a rare cause of invasive disease in Scotland between 1972 and 1998 it is important that microbiologists are aware of its potential for increasing in incidence after the introduction of MenC vaccines [1].
Although there was diversity in the STs recovered between 1972 and 1998, ten of these STs accounted for more than half of the isolates from the study. There is extensive evidence for the persistence of particular genotypes among meningococcal disease isolates [17], [18] and similar observations have been made with other bacterial species [19]. In the present study, clonal complexes associated with seven lineages accounted for 1993 isolates (76.4%). Thus, although there were infections associated with novel STs, the majority of disease was associated with the same predominant disease-associated complexes that have been found worldwide and over a number of years [20], [21]. During the 1980s and 1990s, there was a noted diversity at the complex, ST and singleton levels but there was less diversity in the 1970s. However, these results should be treated with caution as there was a 27% increase in the number of isolates received at the reference laboratory between the 1970s and 1980s, and a similar increase between the 1980s and 1990s which may affect the reported meningococcal diversity.
A number of studies have been performed with collections of meningococci. For example, the EU-MenNet project analysed over 4000 European disease isolates from 18 countries for three years from 2000 to 2002 [21]–[23]. Although its findings were broadly similar to those of the present study, the isolates were from the time period around MenC vaccine implementation. With the increasingly widespread use of meningococcal polysaccharide and conjugate vaccines, one of the continuing epidemiological concerns is the effect of immunisation on serogroup replacement within the meningococcal population [24]. As the first meningococcal serogroup B vaccine has now been licensed in Europe and elsewhere [25], studies on meningococci from carriage and disease remain important in order to monitor circulating meningococcal serogroups.
Acknowledgments
The authors would like to thank the technical assistance of staff at the Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory. This study made use of the Neisseria Multilocus Sequence Typing website (http://pubmlst.org/neisseria) developed by Keith Jolley and Man-Suen Chan and sited at the University of Oxford. The development of this site has been funded by the Wellcome Trust and European Union.
Author Contributions
Conceived and designed the experiments: CBS MAD RLD SCC. Performed the experiments: CBS MAD RLD SCC. Analyzed the data: CBS. Wrote the paper: CBS MAD RLD SCC.
References
- 1. Ladhani SN, Lucidarme J, Newbold LS, Gray SJ, Carr AD, et al. (2012) Invasive meningococcal capsular group Y disease, England and Wales, 2007–2009. Emerg Infect Dis 18:63–70.
- 2. Ladhani SN, Flood JS, Ramsay ME, Campbell H, Gray SJ, et al. (2012) Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine 30:3710–3716.
- 3. Mooney JD, Christie P, Robertson C, Clarke SC (2004) The impact of meningococcal serogroup C conjugate vaccine in Scotland. Clin Infect Dis 39:349–356.
- 4. Diggle MA, Clarke SC (2005) Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines. J Clin Microbiol 43:4649–4653.
- 5. Campbell H, Borrow R, Salisbury D, Miller E (2009) Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 27 Suppl 2B20–29.
- 6. Diggle MA, Clarke SC (2002) Semi-automation of the polymerase chain reaction for laboratory confirmation of meningococcal disease. Br J Biomed Sci 59:137–140.
- 7. Eldridge J, Sutcliffe EM, Abbott JD, Jones DM (1978) Serological grouping of meningococci and detection of antigen in cerebrospinal fluid by coagglutination. Med Lab Sci 35:63–66.
- 8. Borrow R, Claus H, Chaudhry U, Guiver M, Kaczmarski EB, et al. (1998) siaD PCR ELISA for confirmation and identification of serogroup Y and W meningococcal infections. FEMS Microbiol Lett 159:209–214.
- 9. Borrow R, Claus H, Guiver M, Smart L, Jones DM, et al. (1997) Non-culture diagnosis and serogroup determination of meningococcal B and C infection by a sialyltransferase (siaD) PCR ELISA. Epidemiol Infect 118:111–117.
- 10. Diggle MA, Smith K, Girvan EK, Clarke SC (2003) Evaluation of a fluorescence-based PCR method for identification of serogroup a meningococci. J Clin Microbiol 41:1766–1768.
- 11. Sullivan CB, Jefferies JM, Diggle MA, Clarke SC (2006) Automation of MLST using third-generation liquid-handling technology. Mol Biotechnol 32:219–226.
- 12. Diggle MA, Clarke SC (2002) Rapid assignment of nucleotide sequence data to allele types for multi-locus sequence analysis (MLSA) of bacteria using an adapted database and modified alignment program. J Mol Microbiol Biotechnol 4:515–517.
- 13. Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG (2004) eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol 186:1518–1530.
- 14. Ibarz-Pavon AB, Maclennan J, Andrews NJ, Gray SJ, Urwin R, et al. (2011) Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation. J Infect Dis 204:1046–1053.
- 15. Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, et al. (2008) Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 197:737–743.
- 16. Jones DM, Sutcliffe EM (1990) Group A meningococcal disease in England associated with the Haj. J Infect 21:21–25.
- 17. Caugant DA, Froholm LO, Bovre K, Holten E, Frasch CE, et al. (1986) Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc Natl Acad Sci U S A 83:4927–4931.
- 18. Caugant DA (1998) Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 106:505–525.
- 19. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, et al. (2002) The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A 99:7687–7692.
- 20. Achtman M (1995) Epidemic spread and antigenic variability of Neisseria meningitidis. Trends Microbiol 3:186–192.
- 21. Brehony C, Jolley KA, Maiden MC (2007) Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev 31:15–26.
- 22. Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, et al. (2007) A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 31:27–36.
- 23. Trotter CL, Ramsay ME (2007) Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 31:101–107.
- 24. Maiden MC, Spratt BG (1999) Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 354:615–616.
- 25. Martin NG, Snape MD (2013) A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Expert Rev Vaccines 12:837–858.